Clinical Trial Update: A Study With SAGE-547 for Super-Refractory Status Epilepticus [Phase 3]

View source ↗

Summary

Phase 3 study of SAGE-547 (ganaxolone) for super-refractory status epilepticus has completed, with results posted in May 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Super-refractory Status Epilepticus

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Super-Refractory Status Epilepticus | Phase 3 | Status: COMPLETED | Results posted: 2019-05-02